Milvexian did not reduce ischemic risk in recent ACS
MUNICH — Milvexian did not lower risk for ischemic events compared with placebo in patients who experienced a recent ACS, but also did not increase bleeding risk, a speaker reported.
The LIBREXIA trial evaluating the small-molecule factor XIa inhibitor milvexian (Bristol Myers Squibb/Johnson & Johnson) in patients at risk for recurrent ischemic events after an ACS event was halted early for futility, according to results presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine.
“Milvexin is an oral factor XIa